
Flagship Biosciences provides comprehensive tissue profiling through our AI-enabled pathology platform.
Flagship Biosciences, founded with the mission to revolutionize tissue profiling, leverages its AI-enabled pathology platform to provide comprehensive tissue analysis. The company focuses on enhancing biomarker and clinical development programs through innovative spatial biology solutions. Their core product, the cTA® pathology platform, integrates artificial intelligence to deliver precise and actionable insights, catering primarily to the pharmaceutical and biotechnology sectors.
Notable figures affiliated with Flagship Biosciences include leaders in pathology and AI technology, though specific names are not provided. The company has achieved significant milestones, such as partnerships with Offspring Biosciences and sponsorship roles in major industry conferences like the Spatial Biology East Coast Congress. Flagship Biosciences' impact is evident in its pioneering role in spatial biology and its contribution to advancing clinical biomarkers and companion diagnostics.

bioSyntagma
biosyntagma.com

BioAI Health
bioaihealth.com

AtlasXomics
atlasxomics.com

VistaPath Biosystems
vistapath.ai

ProFound Therapeutics
profoundtx.com

PredxBio
predxbio.com

Pathos AI
pathos.com

Ionpath

BigHat Biosciences
bighatbio.com

Alpenglow Biosciences

Manifold Bio
manifold.bio

Cellarity

Singularity.AI
singularity.ai

Ampersand Biomedicines
ampersand.bio

Regenerative Bio
regen-bio.us
Companies similar to Flagship Biosciences include bioSyntagma, BioAI Health, AtlasXomics and VistaPath Biosystems.
Flagship Biosciences was founded in 2009.
Flagship Biosciences' headquarters is located in Westminster, CO, US.
Flagship Biosciences' most recent funding round was for $15.3M (USD) in September 2022.
As of Sep 9, 2022, Flagship Biosciences has raised a total of $15.3M (USD).